Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul 29:14:164.
doi: 10.1186/1471-2369-14-164.

The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

Affiliations
Review

The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

David Gustafsson et al. BMC Nephrol. .

Abstract

Uric acid is the end product of purine metabolism in humans. High levels are causative in gout and urolithiasis. Hyperuricaemia has also been implicated in the pathophysiology of hypertension, chronic kidney disease (CKD), congestive heart failure (CHF), the metabolic syndrome, type 2 diabetes mellitus (T2DM), and atherosclerosis, with or without cardiovascular events. This article briefly reviews uric acid metabolism and summarizes the current literature on hyperuricaemia in cardiovascular disease and related co-morbidities, and emerging treatment options.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of uric acid formation and elimination showing the drugs that can affect both.

References

    1. Choi HK, Mount DB, Reginato AM. Pathogenesis of Gout. Ann Intern Med. 2005;143(7):499–516. doi: 10.7326/0003-4819-143-7-200510040-00009. - DOI - PubMed
    1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi: 10.1056/NEJMra0800885. - DOI - PMC - PubMed
    1. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J. 2008;336:309–312. doi: 10.1136/bmj.39449.819271.BE. - DOI - PMC - PubMed
    1. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med. 2013;64:325–337. doi: 10.1146/annurev-med-080911-105830. - DOI - PubMed
    1. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–371. doi: 10.1053/j.ackd.2012.07.009. - DOI - PMC - PubMed